Alpelisib for lymphangioma, cystic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Jul 2023: Trial registered, NCT05948943
  2. 24 Nov 2023: Trial started, NCT05948943

The trials

NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

State
Under way
Phase
Phase 2 and Phase 3
People
232 planned
Started
24 Nov 2023
Primary completion
31 May 2028
Arms
Adult participants, alpelisib dose 1 (Stage 1), Adult participants, alpelisib dose 2 (Stage 1), Pediatric participants (6-17 years of age), alpelisib dose 2 (Stage 1), Pediatric participants (6-17 years of age), alpelisib dose 3 (Stage 1), Adult participants, alpelisib (Stage 2), Pediatric participants (6-17 years of age), alpelisib (Stage 2), Pediatric participants (0-5 years of age), alpelisib (Stage 2)
Results
None posted
  1. 17 Jul 2023: Trial registered
  2. 24 Nov 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Alpelisib Pill, Piqray, Vijoice.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.